Delivered the first global data for any PD-(L)1xVEGF bispecific immunomodulator candidate in combination with an investigational antibody-drug conjugate in lung cancer, with pumitamig plus elfetabart drozuntecanAdvanced
AUSTIN, Texas, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary - An mRNA-based cancer therapy designed around each patient’s own tumor has delivered positive Phase 3 results. On October 22, Merck and
MAINZ, Germany and SHANGHAI, China, October 26, 2026 – BioNTech SE (NASDAQ:BNTX, "BioNTech")) and DualityBiologics (Suzhou) Co., Ltd. ("DualityBio", HKEX: 9606.HK) announced today that the
Pumitamig plus docetaxel demonstrated encouraging responses in squamous and non-squamous non-small cell lung cancer across PD-L1 expression levels with a confirmed objective response rate of 36.7% following progression
BioNTech enters a clinical trial collaboration with Gilead Sciences with the aim of improving outcomes in patients with PD-L1 low or negative triple-negative breast cancerThe global Phase 3 ROSETTA Breast-01 trial will
MAINZ, Germany, October 20, 2026 (GLOBE NEWSWIRE) – BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) will announce its financial results for the third quarter 2026 on Tuesday, November 3, 2026.
Late-breaking oral presentation will feature first data from the global ROSETTA Lung-107 Phase 2 clinical trial evaluating pumitamig, a PD-L1×VEGF-A bispecific immunomodulator, plus docetaxel in patients with metastatic
BioNTech investors absorbed a 7.13% loss when the AHEAD-MERIT trial of BNT113 missed its progression-free survival primary endpoint. An investigation is underway into whether the Company's statements about its mRNA
AHEAD-MERIT Phase 2/3 clinical trial did not meet its first dual primary endpoint of progression-free survival for the mRNA cancer immunotherapy candidate BNT113 plus pembrolizumab compared with pembrolizumab alone The
NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The antiviral market is entering a period where the need for new treatments is becoming impossible to ignore. Viral outbreaks can
Gotistobart continues to show potential as chemotherapy-free monotherapy to reignite anti-tumor immunity in previously treated patients with squamous non-small cell lung cancer, where median survival with current
2026-2027 COVID-19 vaccine formula targets the XFG variant, in line with FDA guidance to more closely match contemporary circulating variants
Shipping will begin immediately to ensure rapid access to this season’s
2026-2027 COVID-19 vaccine formula targets the XFG variant, in line with FDA guidance to more closely match contemporary circulating variantsShipping will begin immediately to ensure rapid access to this season’s
NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - If watching where cancer treatment is headed, mRNA cancer vaccines are hard to ignore—especially in lung cancer. The basic idea is
Pumitamig plus B7H3-targeting elfetabart drozuntecan delivers the first data in lung cancer for any PD-(L)1xVEGF bispecific immunomodulator combined with an antibody-drug conjugate, underscoring BioNTech’s leadership in
